317 related articles for article (PubMed ID: 32060785)
1. Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01.
Yamashiro H; Iwata H; Masuda N; Yamamoto N; Nishimura R; Ohtani S; Sato N; Takahashi M; Kamio T; Yamazaki K; Saito T; Kato M; Lee T; Kuroi K; Takano T; Yasuno S; Morita S; Ohno S; Toi M;
Breast Cancer; 2020 Jul; 27(4):631-641. PubMed ID: 32060785
[TBL] [Abstract][Full Text] [Related]
2. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡.
Conte P; Frassoldati A; Bisagni G; Brandes AA; Donadio M; Garrone O; Piacentini F; Cavanna L; Giotta F; Aieta M; Gebbia V; Molino A; Musolino A; Ferro A; Maltoni R; Danese S; Zamagni C; Rimanti A; Cagossi K; Russo A; Pronzato P; Giovanardi F; Moretti G; Lombardo L; Schirone A; Beano A; Amaducci L; Bajardi EA; Vicini R; Balduzzi S; D'Amico R; Guarneri V
Ann Oncol; 2018 Dec; 29(12):2328-2333. PubMed ID: 30219886
[TBL] [Abstract][Full Text] [Related]
3. A US Registry-Based Assessment of Use and Impact of Chemotherapy in Stage I HER2-Positive Breast Cancer.
Parsons BM; Uprety D; Smith AL; Borgert AJ; Dietrich LL
J Natl Compr Canc Netw; 2018 Nov; 16(11):1311-1320. PubMed ID: 30442732
[No Abstract] [Full Text] [Related]
4. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
Cadoo KA; Morris PG; Cowell EP; Patil S; Hudis CA; McArthur HL
Clin Breast Cancer; 2016 Dec; 16(6):487-493. PubMed ID: 27622751
[TBL] [Abstract][Full Text] [Related]
5. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
[TBL] [Abstract][Full Text] [Related]
6. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
Cantini L; Pistelli M; Merloni F; Fontana A; Bertolini I; De Angelis C; Bastianelli L; Della Mora A; Santinelli A; Savini A; Maccaroni E; Diodati L; Falcone A; Berardi R
Clin Breast Cancer; 2020 Feb; 20(1):e89-e98. PubMed ID: 31378534
[TBL] [Abstract][Full Text] [Related]
7. 6 versus 12 months of adjuvant trastuzumab in HER2+ early breast cancer: A systematic review and meta-analysis.
Wang BC; Xiao BY; Fan JQ; Lin GH; Wang C; Liu Q; Zhao YX
Medicine (Baltimore); 2021 Mar; 100(10):e24995. PubMed ID: 33725875
[TBL] [Abstract][Full Text] [Related]
8. Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer.
Litvak A; Batukbhai B; Russell SD; Tsai HL; Rosner GL; Jeter SC; Armstrong D; Emens LA; Fetting J; Wolff AC; Silhy R; Stearns V; Connolly RM
Cancer; 2018 May; 124(9):1904-1911. PubMed ID: 29381193
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
10. Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial).
Bellon JR; Guo H; Barry WT; Dang CT; Yardley DA; Moy B; Marcom PK; Albain KS; Rugo HS; Ellis M; Wolff AC; Carey LA; Overmoyer BA; Partridge AH; Hudis CA; Krop I; Burstein HJ; Winer EP; Tolaney SM
Breast Cancer Res Treat; 2019 Jul; 176(2):303-310. PubMed ID: 31004299
[TBL] [Abstract][Full Text] [Related]
11. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
Cameron D; Piccart-Gebhart MJ; Gelber RD; Procter M; Goldhirsch A; de Azambuja E; Castro G; Untch M; Smith I; Gianni L; Baselga J; Al-Sakaff N; Lauer S; McFadden E; Leyland-Jones B; Bell R; Dowsett M; Jackisch C;
Lancet; 2017 Mar; 389(10075):1195-1205. PubMed ID: 28215665
[TBL] [Abstract][Full Text] [Related]
12. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.
O'Sullivan CC; Ballman KV; McCall L; Kommalapati A; Zemla T; Weiss A; Mitchell M; Blinder V; Tung NM; Irvin WJ; Lee M; Goetz MP; Symmans WF; Borges VF; Krop I; Carey LA; Partridge AH
Future Oncol; 2021 Dec; 17(34):4665-4676. PubMed ID: 34636255
[TBL] [Abstract][Full Text] [Related]
13. One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis.
Inno A; Barni S; Ghidini A; Zaniboni A; Petrelli F
Breast Cancer Res Treat; 2019 Jan; 173(2):247-254. PubMed ID: 30317424
[TBL] [Abstract][Full Text] [Related]
14. Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy.
Jeon SH; Shin KH; Kim JH; Kim K; Kim IA; Lee KH; Kim TY; Im SA
Breast Cancer Res Treat; 2018 Dec; 172(3):619-626. PubMed ID: 30209731
[TBL] [Abstract][Full Text] [Related]
15. A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database study.
Kubo M; Kawai M; Kumamaru H; Miyata H; Tamura K; Yoshida M; Ogo E; Nagahashi M; Asaga S; Kojima Y; Kadoya T; Aogi K; Niikura N; Miyashita M; Iijima K; Hayashi N; Yamamoto Y; Imoto S; Jinno H
Breast Cancer Res Treat; 2019 Dec; 178(3):647-656. PubMed ID: 31451979
[TBL] [Abstract][Full Text] [Related]
16. Better predictive value of axillary lymph node (ALN) status after systemic therapy for operable HER2-overexpressing breast cancer: A single-institution retrospective study.
Zhang Y; Mo M; Li JW; Zhou Y; Wu J; Yu KD; Shen ZZ; Shao ZM; Liu GY
Eur J Surg Oncol; 2016 Aug; 42(8):1146-52. PubMed ID: 27365197
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
18. Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer.
Cho JH; Lim JY; Cho JY
World J Gastroenterol; 2017 Nov; 23(41):7407-7414. PubMed ID: 29151694
[TBL] [Abstract][Full Text] [Related]
19. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
Harbeck N; Huang CS; Hurvitz S; Yeh DC; Shao Z; Im SA; Jung KH; Shen K; Ro J; Jassem J; Zhang Q; Im YH; Wojtukiewicz M; Sun Q; Chen SC; Goeldner RG; Uttenreuther-Fischer M; Xu B; Piccart-Gebhart M;
Lancet Oncol; 2016 Mar; 17(3):357-366. PubMed ID: 26822398
[TBL] [Abstract][Full Text] [Related]
20. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
